Monsanto owner Bayer AG said Wednesday it was attempting again to manage and resolve potential future Roundup cancer claims, laying out a $2 billion deal with a group of plaintiffs’ attorneys that Bayer hopes will win approval from a federal judge who rejected a prior plan last summer.
Notably, the deal calls for Bayer to seek permission from the Environmental Protection Agency to add information on the labels of its glyphosate-based products such as Roundup that would provide links to access scientific studies and other information about glyphosate safety.
Additionally, according to Bayer, the plan calls for establishment of a fund that would compensate “qualified claimants” over a four-year program; setting up an advisory science panel whose findings could be used as evidence in potential future litigation; and development of research and diagnostic programs for medical and/or scientific research into the diagnosis and treatment of non-Hodgkin lymphoma.
The plan must be approved by U.S. District Judge Vince Chhabria of the U.S. District Court for the Northern District of California. Chhabria has been overseeing the Roundup multidistrict litigation.
Bayer said qualifying class members over the next four years would be eligible for levels of compensatory awards based on guidelines set forth in the agreement. The “settlement class” refers to people who were exposed to Roundup products but have not yet filed a lawsuit claiming injury from that exposure.
Settlement class members would be eligible for compensation between $10,000 and $200,000, Bayer said.
According to the agreement, the distribution of the settlement fund would break out as follows:
- Compensation fund — at least $1.325 billion.
- Diagnostic accessibility grant program — $210 million.
- Research funding program — $40 million.
- Settlement administration costs, advisory science panel costs, settlement class notice costs, taxes, and escrow agent fees and expenses — up to $55 million.
The proposed settlement plan for future class action litigation is separate from the settlement agreement Bayer made with lawyers for tens of thousands of plaintiffs who have already brought claims alleging exposure to Roundup and other Monsanto glyphosate-based weed killers caused them to develop non-Hodgkin lymphoma.
Bayer has been struggling to figure out how to put an end to the Roundup cancer litigation since buying Monsanto in 2018. The company lost all three trials held to date and lost the early rounds of appeals seeking to overturn the trial losses.
Originally published by U.S. Right to Know.
The post Bayer Floats $2B Deal in Attempt to Head Off Future Roundup Cancer Claims appeared first on Children’s Health Defense.
To help the fight in Canada register:
Help us spread the word, donate or share these vital links below:
To help us with our content and show please donate here:
To see the legal challenge that is happening worldwide:
To see hundreds of hours of doctors speaking out:
Important legal documents to your rights as Canadian citizen:
The most important documentary on what is happening in the world right now:
Proof of Genocide:
Dr. David Martin lays it out for you:
The only proof anyone should need:
Alarming uptick in cancers since jab rollout:
3 times more covid deaths since vaccine rollout:
One America Insurance CEO reports 40% increase in death claims since vaccine rollout:
Donate with Crypto:
Donate Bitcoin to this address
Scan the QR code or copy the address below into your wallet to send some Bitcoin
Donate Ethereum to this address
Scan the QR code or copy the address below into your wallet to send some Ethereum
Donate Xrp to this address
Scan the QR code or copy the address below into your wallet to send some Xrp
Donate Litecoin to this address
Scan the QR code or copy the address below into your wallet to send some Litecoin
Donate Dogecoin to this address
Scan the QR code or copy the address below into your wallet to send some Dogecoin